This study not only reveals the molecular mechanism of BRCA1 in suppressing EMT but also tests the efficacy of inhibitors that target PDGFRβ-PKCα signaling on suppressing BRCA1-deficient tumor initiation and progression. The gene discussed is BRCA1; the disease is neoplasm.